Douglas Fambrough co-founded Dicerna and has served as the Company’s President and Chief Executive Officer since 2010. His background as both a genomic scientist and venture capitalist have been instrumental in Dicerna’s evolution from the early development of its unique GalXC™ platform, to its transformation to a publicly traded biopharmaceutical company.
Prior to Dicerna, Dr. Fambrough specialized in financing innovative life science technology companies as a General Partner with Oxford Bioscience Partners, a Boston-based venture capital firm.
In 2003, Dr. Fambrough and two other investors founded Sirna Therapeutics, a first-generation RNA interference (RNAi) pioneer; he served on Sirna’s board of directors until Merck acquired the company in 2006. On Oxford’s behalf, Dr. Fambrough invested in several ventures, including: Solexa, developer of the dominant ultra-high-throughput DNA sequencing platform, which Illumina acquired; and Xencor, a leader in engineering antibodies to improve their therapeutic properties (Nasdaq: XNCR).
Before joining Oxford Bioscience Partners, Dr. Fambrough spent 10 years as a genomic scientist, most recently at the Whitehead/MIT Center for Genome Research, now known as the Broad Institute. He graduated from Cornell University and obtained his Ph.D. in genetics at the University of California, Berkeley.